For three of the patients, the gastrointestinal tract symptoms were generally mild and limited to a few days following the ibandronate treatment.Tablet compliance of the ibandronate was very good with more than of study Tasosartan patients taking all of their monthly doses.Correlation between changes in bone turnover and BMD.To determine if early changes in bone turnover markers could predict for future changes in BMD, a correlation analysis was done.Changes from baseline in bone turnover markers during the first months were related to subsequent changes from baseline in BMD at months.No significant correlations were Tasosartan observed for either the resorption or formation markers measured. Many of these women will be longterm survivors and are thus at risk from the longterm side effects of treatment such as osteoporos is and fracture. In both the ATAC tr ial, eva luat ing anastrozole, and the BIG trial, studying letrozole, an f to excess annual risk of fracture with the aromatase inhibitor compared with tamoxifen was observed, the magnitude of effect and the biochemical evidence of increased bone turnover in patients treated with an aromatase inhibitor argues strongly for a direct adverse effect of these agents on bone health.In this study, the bone loss observed in patients treated with anastrozole without bisphosphonate therapy was similar to that reported in the ATAC trial at f to per year.In the course of the first year, two women who were previously osteopenic lost BMD and became osteoporotic, indicating that regular monitoring of these patients is essential.The rate of bone turnover was suppressed below baseline values throughout the study period, indicating rapid and sufficient dosing and absorption with the same monthly oral schedule used in the treatment of PMO.In this small study, early changes in bone marker levels did not reliably predict for subsequent changes in BMD and are thus probably not of value in predicting individuals who will experience rapid loss of bone.They do, however, provide indirect evidence of treatment compliance.Treatment with anastrozole alone led to significant increases in all bone turnover markers.Changes were higher than those observed in the ATAC trial, which may be explained by the higher baseline bone density in those recruited to the ATAC trial bone subprotocol. This is the first study to report year data on the use of an oral bisphosphonate for the treatment of aromatase inhibitor induced bone loss.Recently, a preliminary analysis of month data from the SABRE study was presented, indicating that oral risedronate mg weekly may also be an effective treatment in terms of BMD changes at months. Zoledronic acid had also been shown to prevent aromatase inhibitor induced bone loss.In the ZFAST study were observed at months following six monthly infusions of zoledronic acid in addition to treatment with the aromatase inhibitor letrozole, a dose intensity somewhat greater than the mgy used in the treatment of PMO.In this study, indirect comparisons suggest a similar increment in BMD with oral ibandronate to other bisphosphonates.Additionally, in the small number of patients with osteoporosis at baseline, oral ibandronate improved BMD in the majority of patients.